Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once ...

For the second trading session in less than a week, Roche Holding ( RHHBY -6.02%) stock really took it on the chin Wednesday.

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Side effects from the drug known as CT-996 - part of Roche's $2.7 billion acquisition of Carmot in December - were mostly ...